BerGenBio ASA BRRGF
97.09 USD 0.00 (+0.00%)
At closeFeb 25, 2026, 4:00 PM EST
0.025 Day range 97.09
0.025 52-week range 97.09
- YTD
- +0.00%
- 1 year
- +0.00%
- Market cap
- 9.49B
- Profit margin
- -877.36%
- EPS (ttm)
- -204.13
- P/E ratio
- -0.79
- YTD return
- +0.00%
- 1-year return
- +0.00%
- Volume
- 37.30K
- Avg volume
- 3.95K
- Open
- 0.97094
- Previous close
- 97.09
- Day's range
- 0.025 – 97.09
- 52-week range
- 0.025 – 97.09
- Beta
- 1.31
- Earnings date
- May 19, 2026
No chart data for this range yet.
Key statistics
- Enterprise value
- 190.84M
- PEG ratio
- 0.00
- Price / sales
- 15.15
- Price / book
- 3.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -150.82%
Next earnings
May 19, 2026
Expected May 19, 2026. Consensus EPS estimate -80.32.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 19, 2026 | Mar 30, 2026 | -80.32 | — | — | — |
| Feb 19, 2026 | Dec 30, 2025 | -69.29 | — | — | — |
| Nov 19, 2025 | Sep 30, 2025 | -0.55311 | — | — | — |
| Aug 20, 2025 | Jun 30, 2025 | — | -0.06836 | — | — |
| May 21, 2025 | Mar 31, 2025 | — | -0.06412 | — | — |
| Feb 26, 2025 | Dec 31, 2024 | -6.13 | -6.13 | 0.00 | 0.00% |
About BerGenBio ASA
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- NO
- Employees
- 13
- Website
- oncoinvent.com
News
Your note
Sign in to keep a note on BRRGF — it syncs with the Stock Master app.